SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026)
SELLAS Life Sciences (SLS) reported Return on Capital Employed of 35.03% for Q1 2026, up 10252.0% year-over-year from N/an in Q1 2025, and up 28.21% on a QoQ basis from 48.8% in Q4 2025.
SELLAS Life Sciences (SLS) has 13 years of Return on Capital Employed data on file, last reported at 35.03% in Q1 2026.
- Quarterly Return on Capital Employed rose 10252.0% year-over-year to 35.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.03% (up 10252.0% YoY) and the FY2025 annual result came in at 67.53%, up 88295.0% from the prior year.
- Return on Capital Employed climbed to 35.03% in Q1 2026 per SLS's latest filing, from 48.8% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 575.3% in Q4 2023 and bottomed at 4073.41% in Q1 2024.
- The 5-year median for Return on Capital Employed is 300.31% (2022), against an average of 558.39%.
- The widest annual swing landed in 2024, when Return on Capital Employed slumped 368975 bps; it then surged 393586 bps in 2025.
- Tracing SLS's Return on Capital Employed over 5 years: stood at 527.21% in 2022, then surged by 209 bps to 575.3% in 2023, then tumbled by 141 bps to 234.15% in 2024, then jumped by 79 bps to 48.8% in 2025, then advanced by 28 bps to 35.03% in 2026.
- Per Business Quant, the three latest SLS Return on Capital Employed figures stand at 35.03% (Q1 2026), 48.8% (Q4 2025), and 74.81% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -35.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.03% |
| Dec 31, 2025 | -48.80% |
| Sep 30, 2025 | -74.81% |
| Jun 30, 2025 | -98.38% |
| Mar 31, 2025 | -137.55% |
| Dec 31, 2024 | -234.15% |
| Sep 30, 2024 | -321.33% |
| Jun 30, 2024 | -450.16% |
| Mar 31, 2024 | -4,073.41% |
| Dec 31, 2023 | 575.30% |
| Sep 30, 2023 | -2,459.96% |
| Jun 30, 2023 | -354.55% |
| Mar 31, 2023 | -383.66% |
| Dec 31, 2022 | -527.21% |
| Sep 30, 2022 | -266.56% |
| Jun 30, 2022 | -300.31% |
| Mar 31, 2022 | -301.95% |
| Dec 31, 2021 | -93.23% |
| Sep 30, 2021 | -50.28% |
| Jun 30, 2021 | -40.54% |
| Mar 31, 2021 | -40.61% |
| Dec 31, 2020 | -85.15% |
| Sep 30, 2020 | -174.10% |
| Jun 30, 2020 | -186.73% |
| Mar 31, 2020 | -167.00% |
| Dec 31, 2017 | -135.59% |
| Sep 30, 2017 | -21.13% |
| Jun 30, 2017 | -25.00% |
| Mar 31, 2017 | -574.66% |
| Dec 31, 2016 | -47.20% |
| Sep 30, 2016 | -105.03% |
| Jun 30, 2016 | -150.93% |
| Mar 31, 2016 | -107.00% |
| Dec 31, 2015 | -135.06% |
| Sep 30, 2015 | -65.77% |
| Jun 30, 2015 | -56.95% |
| Mar 31, 2015 | -74.20% |
| Dec 31, 2014 | -90.78% |
| Sep 30, 2014 | -93.58% |
| Jun 30, 2014 | -78.54% |
| Mar 31, 2014 | -53.29% |
| Dec 31, 2013 | -104.96% |
| Sep 30, 2013 | -67.48% |
| Jun 30, 2013 | -71.45% |
| Mar 31, 2013 | -54.93% |
| Dec 31, 2012 | -117.99% |